La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Viridian Therapeutics Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Steve Mahoney

Amministratore delegato

US$13.0m

Compenso totale

Percentuale dello stipendio del CEO	0.9%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	3.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22

Viridian Therapeutics Q2 2022 Earnings Preview

Aug 12

Viridian Therapeutics gets a new COO

Jun 23

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve Mahoney rispetto agli utili di Viridian Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$228m
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 13.02M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.30M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Steve con le performance aziendali.

AMMINISTRATORE DELEGATO

Steve Mahoney (53 yo)

less than a year

Mandato

US$13,022,654

Compensazione

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	Nessun dato
Seth Harmon	Senior VP of Finance and Accounting	less than a year	US$6.67m	0.0013% $ 23.3k
Thomas Beetham	Chief Operating Officer	less than a year	US$5.17m	Nessun dato
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Vahe Bedian	Co-Founder & Scientific Advisor	no data	Nessun dato	Nessun dato
Jennifer Tousignant	Chief Legal Officer	less than a year	Nessun dato	Nessun dato
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	Nessun dato	Nessun dato
Melissa Manno	Chief Human Resources Officer	less than a year	Nessun dato	Nessun dato
Anthony Casciano	Chief Commercial Officer	1.4yrs	Nessun dato	Nessun dato
Thomas Ciulla	Chief Medical Officer	1.7yrs	Nessun dato	0.0010% $ 17.8k

0.9yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di VRDN non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	Nessun dato
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Arlene Morris	Independent Director	6.7yrs	US$477.83k	0% $ 0
Victor Ambros	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Stefanie Dimmeler	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Jeffery Molkentin	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Eva van Rooij	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Tomas Kiselak	Independent Chairperson of Board	3.9yrs	US$503.83k	0% $ 0
Jennifer Moses	Independent Director	3.2yrs	US$467.83k	0% $ 0
Peter Harwin	Independent Director	3.9yrs	US$471.83k	0% $ 0

3.9yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VRDN sono considerati esperti (durata media dell'incarico 3.8 anni).

Viridian Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Recent updates

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Price target increased by 7.5% to US$37.81

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

New minor risk - Share price stability

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

Consensus revenue estimates fall by 19%

First half 2024 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Consensus revenue estimates increase by 21%

Price target decreased by 7.3% to US$36.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New minor risk - Share price stability

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Price target decreased by 10% to US$41.36

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 18%

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

President recently bought US$101k worth of stock

Consensus revenue estimates fall by 35%

President recently bought US$160k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Price target increased by 9.1% to US$47.08

Chief Medical Officer exercised options and sold US$708k worth of stock

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Consensus revenue estimates increase by 162%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Viridian Therapeutics board compensation committee approves inducement grants

Consensus forecasts updated

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Price target increased to US$39.22

Viridian Therapeutics Q2 2022 Earnings Preview

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

Viridian Therapeutics gets a new COO